Company: CERO
Filing Date: 2025-01-14
Form Type: 424B3
Source: 0001213900-25-003434
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-14
Form: 424B3
Chunk 0
---
|                                                     | Filed Pursuant to Rule 424(b)(3) |
|                                                     | Registration No. 333-282755      |
| Prospectus Supplement No. 2                         |                                  |
| (To Prospectus dated December 5, 2024               
 Prospectus Supplement No. 1, dated January 7, 2025) |                                  |

<div align='center'>CERO THERAPEUTICS HOLDINGS, INC.

638,563,750 Shares of Common Stock</div>

This prospectus supplement no. 2 (this “Prospectus Supplement”)
amends and supplements the prospectus dated December 5, 2024 (as may be supplemented or amended from time to time, the “Prospectus”)
which forms part of our Registration Statement on Form S-1 (Registration Statement No. 333-282755). This Prospectus Supplement is being
filed to update and supplement the information included or incorporated by reference in the Prospectus with the information contained
in the attached Current Reports on Form 8-K, filed with the Securities and Exchange Commission (the “Securities and Exchange Commission”)
on January 7, 2025 and January 10, 2025 (the “Form 8-Ks”). Accordingly, we have attached the Form 8-Ks to this Prospectus
Supplement.

This Prospectus Supplement updates and supplements the information
in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including
any amendments or supplements thereto. This Prospectus Supplement should be read in conjunction with the Prospectus, and if there is any
inconsistency between the information in the Prospectus and this Prospectus Supplement, you should rely on this Prospectus Supplement.

Our common stock and public warrants are listed on Nasdaq Global Market
and Nasdaq Capital Market (collectively, “Nasdaq”) under the symbols “CERO” and “CEROW,” respectively.
On January 13, 2025, the last quoted sale price of our common stock as reported on Nasdaq was $3.29 per share and the last quoted sale
price of our public warrants as reported on Nasdaq was $0.0158 per warrant.

We are an “emerging growth company” under applicable federal securities laws and will be subject to reduced public company reporting requirements.

Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read